Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib (ONO/GS-4059) in Combination With Other Targeted Anti-cancer Therapies in Subjects With B-cell Malignancies

NCT02457598 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT02457598
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02457598 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib (ONO/GS-4059) in Combination With Other Targeted Anti-cancer Therapies in Subjects With B-cell Malignancies
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Terminated
Start date
June 16, 2015
Completion date
September 25, 2024
Enrollment
203 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell malignancies